Podocin as an early biomarker of atherosclerosis in patients with type 2 diabetes mellitus
https://doi.org/10.51922/2616-633X.2024.8.2.2237
Abstract
Introduction. Diabetic nephropathy, on the one hand, is one of the most common causes of end-stage chronic kidney disease in diabetes mellitus (DM), and on the other hand, a risk factor for the development of cardiovascular complications. Microalbumin has traditionally been used in routine practice to assess renal function and cardiovascular risk, however, many markers are now being identified that are associated with renal dysfunction, one of which is podocin. In this regard, it becomes relevant to study podocin in order to predict the risk of developing cardiovascular diseases in diabetes in the future.
Purpose. To study the relationship between podocin levels and atherosclerotic arterial lesions in patients with type 2 diabetes.
Materials and methods. The study included 316 patients with type 2 diabetes, median age 66.00 [60.00; 72.00] years. The investigation of patients included a standard examination with assessment of podocin levels in urine and ultrasound examination of the brachiocephalic arteries with determination of intima-media thickness (IMT) of the common carotid artery (CCA).
Results. Podocin levels in patients with DT2 were significantly higher compared to the control group (0.615 [0.320; 1.892] vs. 0.240 [0.140; 0.300] ng/ml, p < 0.001). When conducting a correlation analysis of the relationship between podocin and IMT CCA, we established a close direct relationship (r = 0.524 for IMT on the right and r = 0.518 for IMT on the left with p < 0.001). Using the binary logistic regression method, a significant association of podocin with IMT CCA was determined, so with an increase in podocin by 1 ng/ml, the chances of IMT thickening increased by 3.028 times. When assessing the probability of IMT thickening using ROC analysis, a cut-off point for podocin of 0.806 ng/mL was obtained, with a sensitivity and pecificity of 71.0% and 81.0%, respectively. The area under the ROC curve was 0.778 ± 0.047 with 95% CI: 0.686 – 0.871, p < 0.001.
Conclusion. Urinary podocin in urine can be considered as an early marker of atherosclerosis in patients with type 2 diabetes, with a sensitivity of 71% and specificity of 81%.
About the Authors
V. Vasilkova
Gomel State Medical University
Belarus
Belarus
Gomel
T. Mokhort
Belarusian State Medical University
Belarus
Belarus
Minsk
I. Pchelin
Saint Petersburg State University
Russian Federation
Russian Federation
Saint Petersburg
N. A. Pervyshin
Samara State Medical University
Russian Federation
Russian Federation
Samara
Y. A. Borovets
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
Gomel
References
1. Strain W.D., Paldánius P.M. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol, 2021, vol. 20(1), pp. 120. doi: 10.1186/s12933-021-01307-5.
2. Gimeno-Orna J.A., Molinero-Herguedas E., Sánchez-Vaño R., et al. Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes. Diabetes Res Clin Pract, 2006, vol. 74(1), pp. 103-109. doi: 10.1016/j.diabres.2006.03.008.
3. Lamprou S., Koletsos N., Mintziori G. et al. Microvascular and Endothelial Dysfunction in Prediabetes. Life (Basel), 2023, vol. 13(3), pp. 644. doi: 10.3390/life13030644.
4. Nonterah E.A., Boateng D., Crowther N.J., et al. Carotid Atherosclerosis, Microalbuminuria, and Estimated 10-Year Atherosclerotic Cardiovascular Disease Risk in Sub-Saharan Africa. JAMA Netw Open, 2022, vol. 5(4), pp. e227559. doi: 10.1001/jamanetworkopen.2022.7559.
5. Vasilkova V., Pchelin I., Bayrasheva V., et al. The role of inflammatory markers and growth factors in progression of chronic kidney disease in patients with diabetes mellitus. J Renal Inj Prev, 2024, vol. x(x), pp. e32188. doi: 10.34172/jrip.2023.31188.
6. Butt L., Unnersjö-Jess D., Reilly D., et al. In vivo characterization of a podocyte-expressed short podocin isoform. BMC Nephro, 2023, vol. 24(1), pp.378. doi: 10.1186/s12882-023-03420-x.
7. Eid A.A., Habib R.H., Chehab O., et al. Podocyturia: an earlier biomarker of cardiovascular outcomes. Sci Rep, 2022, vol. 12(1), pp. 21563. doi: 10.1038/s41598-022-26162-6.
8. Granier C., Makni K., Molina L. Gene and protein markers of diabetic nephropathy. Nephrol Dial Transplant, 2008, vol. 23, pp. 792-799. doi: 10.1093/ndt/gfm834.
9. Bobkova I.N., Shchukina A.A., Shestakova M.V. Clinical significance of determining urinary excretion of nephrin and podocin in patients with diabetes mellitus. Clinical pharmacology and therapy, 2017, vol. 26(5), pp. 31-36.
10. Bobkova I.N., Shestakova M.V., Schukina A.A Diabetic nephropathy - focus on podocytes damage. Nephrology (saint-petersburg), 2015, vol. 2(19), pp. 33-44.
11. Reddy G.R., Kotlyarevska K., Ransom R.F. The podocyte and diabetes mellitus: is the podocyte key to the origins of diabetic nephropathy? Сurr Opin Nephrol Hypertens, 2008, vol. 17, pp. 32-36. doi: 10.1097/MNH.0b013e3282f2904d.
12. Kriz, W. Podocytes as a target for treatment with ACE inhibitors and/or angiotensin-receptor blockers. Kidney Int, 2004, vol. 65, pp. 333-334. doi. 10.1111/ j.1523-1755.2004.00421.x.
13. Toto R.D., Rinner S., Ram C.V. ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents? Postgrad Med, 2004, vol. 116(2), pp. 11-6,19-22,48. doi: 10.3810/pgm.2004.08.1567.
Review
For citations:
Vasilkova V., Mokhort T., Pchelin I., Pervyshin N.A., Borovets Y.A. Podocin as an early biomarker of atherosclerosis in patients with type 2 diabetes mellitus. Emergency Cardiology and Cardiovascular Risks journal. 2024;8(2):2237–2242. (In Russ.) https://doi.org/10.51922/2616-633X.2024.8.2.2237
Views:
6
Email this article 